Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Emergent BioSolutions Inc. reported full-year 2022 results: revenue $1,100-$1,120 million, net income $(210)-$(190) million.
- Period
- full-year 2022
- Revenue
- $1,100-$1,120 million
- Net income
- $(210)-$(190) million
- Result
- preliminary results
Exact text from the filing
Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul Williams was appointed as Senior Vice President Products Business at Emergent BioSolutions Inc..
- Action
- appointed
- Role
- Senior Vice President Products Business
Exact text from the filing
The Company also announced the appointment of Paul Williams as the Company’s Senior Vice President Products Business, reporting to the Company’s CEO, Robert Kramer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Atul Saran departed as Chief Strategy and Development Officer at Emergent BioSolutions Inc..
- Action
- will cease employment
- Role
- Chief Strategy and Development Officer
Exact text from the filing
Atul Saran, the Company’s Chief Strategy and Development Officer, will cease employment with the Company on or about March 17, 2023.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Emergent BioSolutions Inc. announced a restructuring with charges of $9.0M to $11.0M affecting the Company (approximately 5 percent).
- Type
- restructuring
- Charge
- $9.0M to $11.0M
- Affected area
- the Company
- Headcount
- approximately 5 percent
Exact text from the filing
On January 9, 2023, the Company also announced an organizational restructuring plan (the “Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. The Plan includes a reduction of the Company’s current workforce by approximately 5 percent.
View on SEC.gov